Sign in Create account

GENOMIC VALLEY BIOTECH LIMITED

Healthcare · Pharmaceuticals & Biotechnology

BSE: 539206
₹30.39
▲ 1.39 (4.79%)
Sept. 29, 2026 · BSE · bse_bhavcopy
Quality
51/100
Moderate
Valuation
36/100
Fairly Valued
Momentum
66/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹9 Cr
PE (TTM)
506.5
Industry median 36.1 (152 companies)
Price to Book
2.4
PEG (TTM)
-5.5
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-63.4
Free Cash Flow
₹-0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-37.50%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-91.43%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-72.27%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-40.00%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-57.78%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
8.41
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
5.34
as of Sept. 30, 2025
Industry median 10.58 (182 companies)
Net Margin
39.47%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
39.47%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
14.35%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
0.73%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
1.04%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
0.79%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (0.8%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
4.8%
Low 29.1000 · High 30.3900
1W return
4.4%
Low 27.6500 · High 30.4900
1M return
5.3%
Low 27.2500 · High 31.6900
52W return
-63.4%
Low 27.2500 · High 31.8500
Lifetime High ₹83.0000 (Dec. 24, 2024)
Lifetime Low ₹8.2500 (Jan. 14, 2020)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
29.4
10D
29.5
20D
30.3
50D
33.5
100D
34.8
200D
34.5

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
96.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

29.96
Pivot
First resistance30.82
Second resistance31.25
Third resistance32.11
First support29.53
Second support28.67
Third support28.24
Day RSI47.6
Day MFI34.1
Day MACD-1.50
Day MACD signal-1.90

Beta

1M0.20
3M0.29
1Y0.29
3Y0.47

Price change analysis

↑ 5.3%
Over 1 Month
LowHigh
27.2531.69
↓ -63.4%
Over 3 Months
LowHigh
27.2531.85
↓ -63.4%
Over 6 Months
LowHigh
27.2531.85
↓ -63.4%
Over 1 Year
LowHigh
27.2531.85
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 506.5 (own history: 58.0–1383.3)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹0 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹0.0500

Ranks #177 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter46.06%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 46.06% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 22 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
22 Jan 2026 KIRORI MAL SANGHI Bulk Buy 19,933 24.9900 BSE
25 Oct 2024 YOGESH AGRAWAL Bulk Sell 48,032 98.4600 BSE
23 Oct 2024 SATISH KUMAR SHARMA Bulk Sell 21,978 96.8600 BSE
22 Oct 2024 PURUSHOTHAMAN SHAJI Bulk Buy 18,580 98.4500 BSE
22 Oct 2024 YOGESH AGRAWAL Bulk Sell 20,000 99.1000 BSE
21 Oct 2024 SATISH KUMAR SHARMA Bulk Sell 22,322 99.4100 BSE
18 Oct 2024 PARUL AGRAWAL Bulk Sell 19,756 94.2500 BSE
18 Oct 2024 SATISH KUMAR SHARMA Bulk Sell 25,400 94.2500 BSE
18 Oct 2024 VIKRAMASHOKKUMARJAIN Bulk Buy 79,000 94.2500 BSE
16 Oct 2024 PARUL AGRAWAL Bulk Sell 50,300 92.6100 BSE

All bulk and block deals →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (39.5%)
  • Low financial leverage (Debt/Equity 0.00)

Weaknesses

  • Low Return on Equity (0.8%)
  • Declining revenue YoY (-57.8%)
  • Declining profit YoY (-40.0%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (506.5) -- priced for continued strong execution
  • Down 63.4% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about GENOMIC VALLEY BIOTECH LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.